Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (20.68%) | 43.36% | 40.66% | 40.71% |
+8 more TTM periods Free account |
|
| (6.17%) | 16.35% | 14.42% | 14.35% | ||
ROIC |
(4.48%) | 17.07% | 15.69% | 16.79% | |
Return on Tangible Assets |
(36.99%) | 62.26% | 70.13% | 73.22% | |
Average Days of Receivables |
60.58 | 58.19 | 60.91 | 63.93 | |
Free Cash Flow per Share |
10.41 | 8.24 | 7.60 | 7.37 | |
Free Cash Flow |
12,943.00 | 10,230.00 | 9,456.00 | 9,162.00 | |
Capital Expenditures |
(609.00) | (576.00) | (563.00) | (505.00) | |
Piotroski F-Score |
4.00 | 8.00 | 7.00 | 8.00 | |
| Other line items | |||||
Cash ROIC |
32.92% | 20.29% | 18.15% | 17.99% | |
Accounts Receivable Turnover |
6.19 | 6.51 | 6.31 | 6.01 | |
Accounts Payable Turnover |
9.90 | 8.88 | 8.05 | 7.24 | |
Inventory Turnover |
3.29 | 3.34 | 3.58 | 3.39 | |
Average Days of Payables |
39.57 | 38.35 | 41.86 | 47.64 | |
Days of Inventory on Hand |
114.66 | 113.80 | 103.87 | 105.24 | |
Tax Rate |
0.66 | (0.14) | (0.13) | (0.18) | |
Research and Development Expense of Revenue |
19.91% | 19.48% | 19.70% | 20.14% | |
Selling, General and Administrative Expense of Revenue |
21.42% | 20.07% | 19.61% | 20.24% | |
Share Based Compensation of Revenue |
2.98% | 3.04% | 3.04% | 3.05% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(4.18) | 1.17 | 1.18 | 1.19 | |
Depreciation/Fixed assets |
0.47 | 0.49 | 0.49 | 0.50 | |
Capex/Depreciation |
(0.22) | (0.21) | (0.20) | (0.18) | |
Revenue per Share |
24.50 | 23.94 | 23.67 | 23.40 | |
Operating CF per Share |
10.90 | 8.70 | 8.05 | 7.78 | |
Capex per Share |
(0.49) | (0.46) | (0.45) | (0.41) | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.02 | |
Net Profit Margin |
(10.64%) | 30.99% | 28.90% | 27.88% |
Columns are period end dates